Ambrisentan, a non-peptide endothelin receptor antagonist

Cardiovascular Drug Reviews

Volumn 24, Issue 1, 2006, Pages 63-76

  Vatter, Hartmut ^a   Seifert, Volker ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Ambrisentan; Endothelin; Endothelin receptor antagonists; LU 208075

Indexed keywords

4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; CLAZOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; LU 208075; NIMODIPINE; TAK 044; TEZOSENTAN; UNCLASSIFIED DRUG; ENDOTHELIN A RECEPTOR; PHENYLPROPIONIC ACID DERIVATIVE;

BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; FLUSHING; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER ISCHEMIA; LIVER TOXICITY; NAUSEA; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPERFUSION INJURY; RESTENOSIS; REVIEW; SIDE EFFECT; ANIMAL; CHEMISTRY; CHO CELL; CRICETULUS; DRUG ANTAGONISM; HAMSTER; HEART MUSCLE ISCHEMIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CLINICAL TRIALS; CRICETINAE; CRICETULUS; HUMANS; KIDNEY FAILURE; MYOCARDIAL ISCHEMIA; PHENYLPROPIONATES; RECEPTOR, ENDOTHELIN A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247847802     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2006.00063.x     Document Type: Review

References (96)

1. Amberg W, Hergenroder S, Hillen H, et al. LU 208075 and LU 302146, two novel ETA-selective endothelin receptor antagonists: SAR of 3,3-diaryl propionic acid derivatives. 6th International Conference on Endothelin 1999 P20.
2. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet 2004 364 : 347 354.
3. Bax WA, Saxena PR. The current endothelin receptor classification: Time for reconsideration Trends Pharmacol Sci 1994 15 : 379 386.
4. Behrend M. The endothelin receptor antagonist TAK-044 in the treatment of reperfusion injury in organ transplantation. Exp Opin Invest Drugs 1999 8 : 1079 1091.
5. Benigni A. Endothelin antagonists in renal disease. Kidney Int 2000 57 : 1778 1794.
6. Billman GE. Ambrisentan (Myogen). Curr Opin Invest Drugs 2002 3 : 1483 1486.
7. Birck R, Knoll T, Braun C, et al. Improvement of postischemic acute renal failure with the novel orally active endothelin-A receptor antagonist LU 135252 in the rat. J Cardiovasc Pharmacol 1998 32 : 80 86.
8. Bolli MH, Marfurt J, Grisostomi C, et al. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J Med Chem 2004 47 : 2776 2795.
9. Boss C, Bolli M, Weller T : Endothelin receptor antagonists: Structures, synthesis, selectivity and therapeutic applications. Curr Med Chem 2002 9 : 349 383.
10. Brochu E, Lacasse S, Moreau C, et al. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant 1999 14 : 1881 1888.
11. Cernacek P, Franchi L, Dupuis J, Rouleau JL, Levy M. Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clin Chem 1998 44 : 1666 1673.
12. Chow M, Dumont AS, Kassell NF. Endothelin receptor antagonists and cerebral vasospasm: An update. Neurosurgery 2002 51 : 1333 1341.
13. Chuquet J, Benchenane K, Toutain J, MacKenzie ET, Roussel S, Touzani O. Selective blockade of endothelin-B receptors exacerbates ischemic brain damage in the rat. Stroke 2002 33 : 3019 3025.
14. Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: Do they explain the long-term benefit Ann Med 2003 35 : 605 613.
15. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994 270 : 228 235.
16. Clozel M, Ramuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999 290 : 840 846.
17. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 2002 95 : 221 238.
18. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002 165 : 398 405.
19. Ertl G, Bauersachs J. Endothelin receptor antagonists in heart failure: Current status and future directions. Drugs 2004 64 : 1029 1040.
20. Feger GI, Schilling L, Ehrenreich H, Wahl M. Endothelin-induced contraction and relaxation of rat isolated basilar artery: Effect of BQ-123. J Cereb Blood Flow Metab 1994 14 : 845 852.
21. Feger GI, Schilling L, Ehrenreich H, Wahl M. E ndothelium-dependent relaxation counteracting the contractile action of endothelin-1 is partly due to ETB receptor activation. Res Exp Med (Berl) 1997 196 : 327 337.
22. Findlay JM, Deagle GM. Causes of morbidity and mortality following intracranial aneurysm rupture. Can J NeurolSci 1998 25 : 209 215.
23. Gabel G, Uhlmann D, Teupser D, et al. Influence of a selective endothelin(A) receptor antagonist on the quantitative mRNA expression and the immunohistochemistry of vasoactive mediators after pancreas transplantation. Transplant Proc 2003 35 : 2137 2138.
24. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005 46 : 529 535.
25. Goto M, Takei Y, Kawano S, et al. Endothelin-1 is involved in the pathogenesis of ischemia/([a-z])eperfusion liver injury by hepatic microcirculatory disturbances. Hepatology 1994 19 : 675 681.
26. Gottmann, U, van der Woude, FJ, Braun C. Endothelin receptor antagonists: A new therapeutic option for improving the outcome after solid organ transplantation Curr Vasc Pharmacol 2003 1 : 281 299.
27. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: Endothelin receptor antagonism. Ann Rheum Dis 2004 63 : 1009 1014.
28. Hansen-Schwartz J, Hoel NL, Zhou M, Xu CB, Svendgaard NA, Edvinsson L. Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries. Neurosurgery 2003 52 : 1188 1194.
29. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998 16 : 1081 1098.
30. Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: A case for treatment. Proc Am Thorac Soc 2005 2 : 12 19.
31. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: A systematic review. Stroke 1997 28 : 660 664.
32. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure Int J Cardiol 2002 85 : 195 197.
33. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: Randomized intravenous TeZosentan (an endothelin-A/([A-Z]) antagonist) for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003 41 : 204 210.
34. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. Hepatology 1995 21 : 1138 1143.
35. Kirchengast M. Endothelin receptor blockade and in-stent restenosis. J Cardiovasc Pharmacol 2001 38 (Suppl2 S31 S34.
36. Kirchengast M, Luz M. Endothelin receptor antagonists: Clinical realities and future directions. J Cardiovasc Pharmacol 2005 45 : 182 191.
37. Kirchengast M, Munter K. Endothelin and restenosis. Cardiovasc Res 1998 39 : 550 555.
38. Kitazono T, Heistad DD, Faraci FM. D in vivo. J Pharmacol Exp Ther 1995 273 : 1 6.
39. Knoll T, Schult S, Birck R, et al. Therapeutic administration of an endothelin-A receptor antagonist after acute ischemic renal failure dose-dependently improves recovery of renal function. J Cardiovasc Pharmacol 2001 37 : 483 488.
40. Kolettis TM, Kyriakides ZS, Leftheriotis D, Papalambrou A, Kremastinos DT, Webb DJ. Electrophysiologic effects of endothelin receptor-A blockade in patients with coronary artery disease. JInterv Card Electrophysiol 2003 8 : 173 179.
41. Korn JH, Mayes M, Matucci CM, et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004 50 : 3985 3993.
42. Krum H, Denver R, Tzanidis A, Martin P. Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Fail Rev 2001 6 : 341 352.
43. Krum H, Liew D. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. Curr Opin Invest Drugs 2003 4 : 298 302.
44. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998 338 : 784 790.
45. Kyriakides ZS, Psychari SN, Kolettis TM, Georgiadis M, Antoniadis A, Kremastinos DT. Usefulness of endothelin(A) receptor antagonists for the prevention of in-stent restenosis in patients with stable angina pectoris or silent myocardial ischemia. Am J Cardiol 2003 91 : 476 479.
46. Lee SH, Channick RN. Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Merf 2005 26 : 402 408.
47. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005 258 : 199 215.
48. Liu C, Cheng J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2005 CD004434.
49. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: The Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002 106 : 2666 2672.
50. Martignoni ME, Ceyhan GO, Ayuni E, et al. Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis. Langenbeck's Arch Surg 2004 389 : 184 192.
51. Masuda Y, Sugo T, Kikuchi T, et al. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl)carbonyl]-L-alanyl-L-alpha- aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelin A and endothelin B receptors. J Pharmacol Exp Ther 1996 279 : 675 685.
52. Moreland S, McMullen DM, Delaney CL, Lee VG, Hunt JT. V enous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun 1992 184 : 100 106.
53. Morimoto H, Shimadzu H, Kushiyama E, et al. Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives. J Med Chem 2001 44 : 3355 3368.
54. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1999 1 : 197 200.
55. Nilsson T, Cantera L, Adner M, Edvinsson L. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries. Neurosurgery 1997 40 : 346 351.
56. O'Callaghan D, Gaine SP. Bosentan: A novel agent for the treatment of pulmonary arterial hypertension. Int J Clin Pract 2004 58 : 69 73.
57. O'Connor CM, Gattis WA, Adams, KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: Results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003 41 : 1452 1457.
58. Pannen BH, Bauer M, Noldge-Schomburg GF, et al. Regulation of hepatic blood flow during resuscitation from hemorrhagic shock: Role of NO and endothelins. Am J Physiol 1997 272 : H2736 H2745.
59. Pollock DM. Endothelin antagonists in the treatment of renal failure. Curr Opin Invest Drugs 2001 2 : 513 520.
60. Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3- diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997 282 : 1312 1318.
61. Rabinstein AA, Pichelmann MA, Friedman JA, et al. Symptomatic vasospasm and outcomes following aneurysmal subarachnoid hemorrhage: A comparison between surgical repair and endovascular coil occlusion. J Neurosurg 2003 98 : 319 325.
62. Raschack M, Unger L, Riechers H, Klinge D. Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol 1995 26 (Suppl3 S397 S399.
63. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: Promises and frustrations. Nat Rev Drug Discov 2002 1 : 986 1001.
64. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003 108 : 2184 2190.
65. Riechers H, Albrecht HP, Amberg W, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 1996 39 : 2123 2128.
66. Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: General pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997 283 : 1110 1118.
67. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994 46 : 325 415.
68. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990 348 : 732 735.
69. Salom JB, Torregrosa G, Alborch E. Endothelins and the cerebral circulation. Cerebrovasc Brain Metab Rev 1995 7 : 131 152.
70. Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 2001 142 : 340 349.
71. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol 2005 43 : 19 29.
72. Schilling L, Feger GI, Ehrenreich H, Wahl M. E ndothelin-3-induced relaxation of isolated rat basilar artery is mediated by an endothelial ETB-type endothelin receptor. J Cereb Blood Flow Metab 1995 15 : 699 705.
73. Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 1995 82 : 55 62.
74. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: A report by the Steering Committee on behalf of the UK/([A-Z])etherlands/([a-z])ire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000 93 : 992 997.
75. Siren AL, Lewczuk P, Hasselblatt M, Dembowski C, Schilling L, Ehrenreich H. Endothelin B receptor deficiency augments neuronal damage upon exposure to hypoxia-ischemia in vivo. Brain Res 2002 945 : 144 149.
76. Tanaka K, Higuchi H, Karasawa F, Sato T. Effects of selective and non-selective endothelin antagonists on ischemia-reperfusion damage in the isolated perfused murine liver. Res Commun Mol Pathol Pharmacol 1999 103 : 129 138.
77. Teerlink JR. Endothelins: Pathophysiology and treatment implications in chronic heart failure. Curr Heart Fail Rep 2005 2 : 191 197.
78. Teerlink JR, McMurray JJ, Bourge RC, et al. Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005 150 : 46 53.
79. Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 2001 120 : 460 466.
80. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003 42 : 140 147.
81. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001 103 : 973 980.
82. Tostes RC, Muscara MN. Endothelin receptor antagonists: Another potential alternative for cardiovascular diseases. Curr Drug Targets Cardiovasc Haematol Disord 2005 5 : 287 301.
83. Trenkner J, Priem F, Bauer C, Neumayer HH, Raschak M, Hocher B. Endothelin receptor A blockade reduces proteinuria and vascular hypertrophy in spontaneously hypertensive rats on high-salt diet in a blood-pressure- independent manner. Clin Sci (Lond) 2002 103 (Suppl 48 385S 388S.
84. Uhlmann D, Gabel G, Ludwig S, et al. Effects of ET(A) receptor antagonism on proinflammatory gene expression and microcirculation following hepatic ischemia/([a-z])eperfusion. Microcirculation 2005 12 : 405 419.
85. Uhlmann D, Gaebel G, Armann B, et al. Attenuation of proinflammatory gene expression and microcirculatory disturbances by endothelin A receptor blockade after orthotopic liver transplantation in pigs. Surgery 2006 139 : 61 72.
86. Uhlmann D, Glasser S, Gaebel G, et al. Improvement of postischemic hepatic microcirculation after endothelin A receptor blockade - endothelin antagonism influences platelet-endothelium interactions. J Gastrointest Surg 2005 9 : 187 197.
87. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005 103 : 9 17.
88. Vatter H, Zimmermann M, Seifert V, Schilling L. Experimental approaches to evaluate endothelin-A receptor antagonists. Meth Find Exp Clin Pharmacol 2004 26 : 277 286.
89. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: Inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg 2005 102 : 1101 1107.
90. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Seifert V, Schilling L. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: Effect on endothelin(B) receptor-mediated relaxation. J Neurosurg 2005 102 : 1108 1114.
91. Vatter H, Zimmermann M, Weyrauch E, et al. Cerebrovascular characterization of the novel nonpeptide en-dothelin-A receptor antagonist LU 208075. Clin Neuropharmacol 2003 26 : 73 83.
92. Witzigmann H, Ludwig S, Escher E, et al. Administration of a selective endothelin-A receptor antagonist (BSF 208075) improves hepatic warm ischemia/([a-z])eperfusion injury in pigs. Transplant Proc 2002 34 : 2387 2388.
93. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 332 : 411 415.
94. Yuyama H, Noguchi Y, Fujimori A, et al. S uperiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol 2004 498 : 171 177.
95. Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: An overview. Neurosurgery 1998 43 : 863 875.
96. Zuccarello M, Boccaletti R, Romano A, Rapoport RM. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 1998 29 : 1924 1929.